These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29943121)

  • 1. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients.
    Lee DY; Kim JY; Yu J; Kim SW
    Front Oncol; 2020; 10():863. PubMed ID: 32656076
    [No Abstract]   [Full Text] [Related]  

  • 3. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Menstruation or the Serum Hormone Level a Useful Predictor for Live Birth after Gonadotropin-Releasing Hormone Agonist during Chemotherapy in Young Breast Cancer Patients.
    Lee DY; Choi D
    Gynecol Obstet Invest; 2017; 82(6):601-606. PubMed ID: 28006769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
    Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antral follicle count recovery in women with menses after treatment with and without gonadotropin-releasing hormone agonist use during chemotherapy for breast cancer.
    Sinha N; Letourneau JM; Wald K; Xiong P; Imbar T; Li B; Harris E; Mok-Lin E; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Oct; 35(10):1861-1868. PubMed ID: 30066303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
    Wang SY; Wang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
    Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
    Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer.
    Kim SE; Kim WJ; Choi D; Lee DY
    Breast Cancer Res Treat; 2023 Apr; 198(2):231-237. PubMed ID: 36781519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
    Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
    Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
    Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
    Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
    Zhang F; Liu XL; Rong N; Huang XW
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GnRH agonist therapy to protect ovarian function in young Korean breast cancer patients.
    Park HJ; Koo YA; Im YH; Yoon BK; Choi D
    J Korean Med Sci; 2010 Jan; 25(1):110-6. PubMed ID: 20054409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity.
    Ben-Aharon I; Granot T; Meizner I; Hasky N; Tobar A; Rizel S; Yerushalmi R; Ben-Haroush A; Fisch B; Stemmer SM
    Oncologist; 2015 Sep; 20(9):985-91. PubMed ID: 26099742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.